A Phase 4 interventional study of Propofol Injection and Ciprofol Injection in Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia, sponsored by General Hospital of Ningxia Medical University. Recruiting at 1 site in China. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by General Hospital of Ningxia Medical University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
At the initiation of induction for non-intubated general anesthesia, ciprofol or propofol will be administered intravenously at a rate of 10 mL/min. The Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale will be used to evaluate sedation depth. This study aims to assess the effects of ciprofol and propofol on hemodynamics and respiratory function in elderly patients undergoing non-intubated general anesthesia.
Inclusion Criteria (1)Elderly patients scheduled to undergo gastrointestinal endoscopy; (2)Aged 65-80 years; (3)American Society of Anesthesiologists (ASA) status of Ⅰ-Ⅲ; Exclusion Criteria
Baseline Demographic Data Gender, age, height, weight, BMI, ASA classification, smoking history, alcohol consumption, underlying diseases, Modified Mallampati score, thyromental distance, snoring history, etc.
Outcome Measures
(1)Altered ventilation: respiratory rate (RR)\<8 bpm, or PETCO₂ decreased by more than 50% from baseline and lasting>30 s; (2)Apnea: cessation of thoracic movement during the procedure, or abruptly flattened PETCO₂ waveform lasting>15 s; (3)Hypoxemia: SpO₂\<93% lasting>15 s; (4)Severe hypoxemia: SpO₂ ≤ 85%. Anesthetic Protocol All patients maintained an 8-hour fast and a 4-hour liquid restriction preoperatively, with no preoperative medications administered. Standardized bowel preparation was completed within 24 hours.
After entering the room, the patients were placed in the left lateral position, received oxygen via nasal cannula at 6 L/min, and an upper extremity venous access was established. The non-invasive continuous arterial pressure and cardiac output monitoring system (Model:NICAP-T20A,Hunan Manite Medical Equipment Co., Ltd.) was used for continuous hemodynamic monitoring. A standard NIBP cuff was placed on the left upper arm for regular calibration. An ear clip sensor was attached to the right ear (the long handle end was placed inside the ear cavity close to the ear hole, and the curved end closely fitted the back of the ear), and a toe clip sensor was fixed at the root of the second or third toe of the right foot for continuous measurement. The system was manually calibrated every 1 min using brachial arterial blood pressure as the reference standard. The NICAP system continuously monitored hemodynamic parameters including systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), stroke volume (SV), cardiac output (CO), and systemic vascular resistance (SVR).Ventilation was monitored using a sidestream capnography (Model:KMI605C,Kingst). A pulse oximetry probe was connected, and a transnasal carbon dioxide sampling catheter was placed at the nasal vestibule to continuously sample exhaled gas. Respiratory rate (RR), pulse oxygen saturation (SpO₂), end-tidal carbon dioxide (PETCO₂) were recorded continuously.
Midazolam(Jiangsu Nhwa Pharmaceutical Co., Ltd.) 0.01 mg/kg was injected intravenously first. After the patient's circulation and respiration stabilized, the measured values were recorded as baseline data(T0). Ciprofol(Haisco Pharmaceutical Group Co., Ltd.) or propofol(Xi'an Libang Pharmaceutical Co., Ltd. ) was then infused intravenously at a rate of 10 mL/min. The modified observer's assessment of alertness/sedation (MOAA/S) scale was used to assess sedation depth every 5 seconds. Loss of consciousness was defined as MOAA/S score ≤ 1, at which drug administration was stopped, and the total induction dose of ciprofol or propofol was recorded. SBP, DBP, MAP, HR, SV,CO,SV and SVR were recorded at time points: before drug administration(T0), immediately after loss of consciousness(T1), immediately at endoscope insertion(T2), 1 min(T3), 2 min(T4), 3 min(T5), 4 min(T6) and 5 min(T7) after loss of consciousness. The incidence of respiratory-related adverse event was documented simultaneously. During anesthesia, anesthesiologists administered additional boluses of one-third of the initial induction dose of ciprofol or propofol according to the patient's responses such as eye opening, verbal response and body movement, with an interval of at least 1 min between injections.
During anesthesia, hypotension (SBP \< 90 mmHg, or MAP decreased by more than 20% from baseline and lasting >2 min) was treated with intravenous ephedrine 6 mg. Bradycardia (HR \< 45 bpm lasting >30 s) was managed with intravenous atropine 0.5 mg. In the event of altered ventilation (RR\< 8 bpm or PETCO₂ decreased by more than 50% from baseline and lasting > 30 s), apnea (cessation of thoracic movement or abruptly flattened PETCO₂ waveform lasting>15 s), hypoxemia (SpO₂ \< 93% lasting > 15 s), or severe hypoxemia ( SpO₂ ≤ 85%) . Anesthesiologists performed jaw thrust, increased oxygen flow, or provided mask-assisted ventilation; tracheal intubation was performed if necessary.
General Hospital of Ningxia Medical University is the lead sponsor of 111 studies on the registry; 44 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 6, 2026. See what changed
Inclusion Criteria
(1)Declined to participate in the study; (2)Had known allergies or to benzodiazepines, ciprofol, propofol, or related compounds; (3)Had a history of alcohol abuse or dependence on sedative-hypnotics drugs; (4)Severe cardiovascular diseases, including uncontrolled hypertension(SBP ≥160 mmHg or DBP ≥100 mmHg despite medical treatment) or hypotension (SBP ≤90 mmHg or DBP ≤60 mmHg), resting bradycardia (heart rate \< 45 bpm), severe arrhythmia, heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction within the past 6 months, third-degree atrioventricular block, and ≥ 450 ms; (5)Severe respiratory diseases, including respiratory insufficiency and (COPD), bronchospasm requiring treatment within the previous 3 months, acute respiratory infection accompanied by fever, wheezing, pulmonary rales or cough within the past week, predicted difficult airway(Mallampati grade Ⅳ), and baseline hypoxemia (SpO₂ \< 90%); (6)Liver, kidney, blood system, nervous system, metabolic system or mental diseases with significant clinical significance; (7)Severe gastrointestinal diseases such as gastric retention and persistent gastrointestinal bleeding; (8)Demonstrated uncooperative behavior or impaired communication ability.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group plans to enroll a total of 54 elderly patients aged 65-80 who will undergo brief procedures without intubation, using spontaneous respiration under general anesthesia. The intravenous infusion of cyclopropane hydrochloride injection will be administered at a constant rate of 10 ml/min. The administration will cease when the MOAA/S score is ≤1. Throughout the procedure, hemodynamic parameters (HR, SBP, DBP, MAP, CO, SV,SVR) will be monitored within the first 5 minutes after induction. The incidence of respiratory-related adverse event was documented simultaneously. The safety of the medication will be evaluated in comparison with the control group
Drug: Ciprofol Injection
This study aims to enroll 54 elderly patients aged 65-80 with short procedures and no need for intubation, who will receive propofol intravenously at a constant rate of 10 ml/min until their MOAA/S score drops to ≤1 point. Throughout the procedure, hemodynamic parameters (HR, SBP, DBP, MAP, CO, SV,SVR) will be monitored within the first 5 minutes after induction. The incidence of respiratory-related adverse event was documented simultaneously. This will allow for a parallel comparison of the two medications' effects on the circulatory and respiratory systems of elderly patients with the propofol control group.
Drug: Propofol Injection
Intravenous administration, injection rate of 10 ml/min, continuous and uniform infusion until the patient's MOAA/S sedation score is ≤1 point. This is used for the induction of general anesthesia in short-duration medical procedures for elderly individuals aged 65-80 without intubation and with spontaneous respiration
Intravenous administration, injection rate of 10 ml/min, continuous and uniform infusion until the patient's MOAA/S sedation score is ≤1 point. This is used for the induction of general anesthesia in short-duration medical procedures for elderly individuals aged 65-80 without intubation and with spontaneous respiration
Comparison of hemodynamic and respiratory function changes within 5 minutes of anesthesia induction
The primary objective of this study was to evaluate the degree of circulatory and respiratory suppression induced by two types of anesthesia drugs in elderly patients. Continuous, non-invasive monitoring was conducted on the baseline conditions before administration for patients aged 65 to 80 undergoing short procedures without intubation and with spontaneous respiration under general anesthesia. Additionally, measurements were taken at 1 minute, 2 minutes, 3 minutes, 4 minutes, and 5 minutes after induction to assess circulatory and respiratory functions. Statistical analysis was performed to compare the changes in Heart rate, systolic blood pressure, diastolic blood pressure, mean arterial pressure, cardiac output , stroke volume, systemic vascular resistance , peripheral oxygen saturation within the 5-minute induction period and incidence of respiratory-related adverse events.
Time frame: 5 minutes after induction of anesthesia
Other adverse events:
Other adverse events: injection pain, cough, hypotension (SBP\<90 mmHg, or MAP decreased by more than 20% from baseline and lasting \>2 min), bradycardia (HR \< 45 bpm lasting \>30 s).
Time frame: during anesthesia
Started Jul 2026 (actual). Primary completion is estimated for Feb 2027, 7 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ciprofol
General Hospital of Ningxia Medical University →